FDA Fast Tracks Acceleron’s Muscle Disease Drug

Acceleron’s protein therapeutic, ACE-031, has received fast track designation by the FDA. Developed for the treatment of neuromuscular disease, ACE-031 has shown promise in increasing muscle mass, strength, and physical use in animal models and is currently in a Phase II trial for Duchenne Muscular Dystrophy.

Click here to read more.

Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail